What is ProPhase Labs?
Established in 1989 and headquartered in Doylestown, PA, ProPhase Labs operates as a diversified medical science and technology entity. The company possesses extensive experience in the development and distribution of over-the-counter (OTC) consumer healthcare products and dietary supplements. Its long-standing history in the industry positions it as a notable player in the health and wellness market.
How much funding has ProPhase Labs raised?
ProPhase Labs has raised a total of $63.7M across 7 funding rounds:
Debt
$1.5M
Debt
$10M
Stock Offering
$37.5M
Multiple Rounds
$14.7M
Debt (2015): $1.5M, investors not publicly disclosed
Debt (2020): $10M, investors not publicly disclosed
Stock Issuance/Offering (2021): $37.5M, investors not publicly disclosed
Debt (2025): $1M, investors not publicly disclosed
Debt (2025): $3M, investors not publicly disclosed
Debt (2025): $3M, investors not publicly disclosed
Other Financing Round (2025): $7.7M led by Keystone Capital Partners
Key Investors in ProPhase Labs
Keystone Capital Partners
Keystone Capital Partners New York is a New York City-based investment firm that provides tailor-made solutions to facilitate long-term growth. The firm specializes in helping overlooked companies achieve their goals. Their services are designed to support businesses in reaching their full potential.
What's next for ProPhase Labs?
The substantial enterprise-level funding and recent strategic investment indicate a phase of significant growth and potential expansion for ProPhase Labs. This capital infusion is likely to fuel advancements in product development, market penetration, and technological innovation within its core areas of OTC consumer healthcare and dietary supplements. The company is poised to leverage this financial backing to further solidify its market position and explore new opportunities in the evolving health sciences landscape.
See full ProPhase Labs company page
